SRZN
Surrozen, Inc./DECompany Information
- Company Name
- Surrozen, Inc./DE
- CIK
- CIK0001824893
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- SRZN: Nasdaq, SRZNW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- SRZN
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-24
- Last sale
- 2026-07-22
- Shares purchased (TTM)
- 883,328
- Shares sold (TTM)
- 335,828
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 10,403,686
- Shares outstanding
- 11,663,000
- Ownership
- 89.20%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 3.60%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 102 | 107 | 89 | 81 | 90 | 102 | 35 | 31 | 38 | 27 | 36 | 34 | ||||||
| Accounts Receivable Net Current | 5 | 5 | 0 | 2 | 2 | 2 | 2 | 12 | 2 | 2 | 2 | 2 | ||||||
| Marketable Securities Current | - | - | - | - | - | - | - | - | - | - | 0 | 9 | ||||||
| Accounts Receivable- Related Party | - | - | 3 | 1 | 1 | 1 | 1 | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | ||||||
| Assets Current | 109 | 114 | 92 | 86 | 94 | 106 | 39 | 45 | 42 | 32 | 41 | 48 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Operating Lease Right Of Use Asset | 5 | 6 | 6 | 6 | 7 | 7 | 8 | 1 | 1 | 2 | 2 | 2 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | ||||||
| Assets | 116 | 121 | 99 | 94 | 103 | 115 | 48 | 48 | 45 | 37 | 46 | 54 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | ||||||
| Accrued Liabilities Current | 6 | 7 | 8 | 5 | 4 | 9 | 5 | 4 | 4 | 3 | 4 | 4 | ||||||
| Operating Lease Liability Current | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 3 | 2 | 2 | ||||||
| Liabilities Current | 9 | 10 | 10 | 7 | 6 | 11 | 7 | 6 | 6 | 6 | 7 | 7 | ||||||
| Operating Lease Liability Noncurrent | 4 | 5 | 5 | 6 | 6 | 7 | 7 | 0 | 0 | 0 | 1 | 2 | ||||||
| Derivative Liabilities | 196 | 236 | 159 | 52 | 11 | 42 | 0 | - | - | - | - | - | ||||||
| Liabilities | 334 | 399 | 286 | 118 | 56 | 109 | 70 | 42 | 39 | 7 | 8 | 8 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 386 | 377 | 340 | 321 | 320 | 318 | 264 | 263 | 262 | 261 | 260 | 258 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -605 | -655 | -527 | -344 | -272 | -312 | -285 | -257 | -256 | -231 | -222 | -213 | ||||||
| Stockholders Equity | -219 | -278 | -188 | -24 | 47 | 6 | -21 | 6 | 6 | 30 | 38 | 46 | ||||||
| Liabilities And Stockholders Equity | 116 | 121 | 99 | 94 | 103 | 115 | 48 | 48 | 45 | 37 | 46 | 54 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 12 | 11 | 10 | 9 | 9 | 8 | 3 | 3 | 3 | 2 | 2 | 2 | ||||||
| Shares Outstanding | 12 | 11 | 10 | 9 | 9 | 8 | 3 | 3 | 3 | 2 | 2 | 2 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialSurrozen, Inc./DE (SRZN) — SEC Financial Statements & Analysis
Surrozen, Inc./DE (SRZN) is a biological products, (no diagnostic substances) company, incorporated in DE. Surrozen, Inc./DE trades on Nasdaq as: SRZN, SRZNW. Surrozen, Inc./DE (SRZN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Surrozen, Inc./DE carries a market cap of $302.65M, a P/E ratio of -0.96x, a P/B ratio of -1.38x, a P/S ratio of 26.29x, an enterprise value of $199.98M, and an EV/EBITDA multiple of -4.53x. On profitability, it posts an operating margin of -385.28%, a net margin of -2729.49%, a Return on Equity (ROE) of 366.30%, a Return on Assets (ROA) of -287.85%, and a Return on Invested Capital (ROIC) of -215.69%. Per share, it reports EPS of $-26.94, diluted EPS of $-13.57, free cash flow per share of $-3.00, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -8.79% year-over-year, net income growth of 807.15% year-over-year, and EPS growth of 564.32% year-over-year. On the balance sheet, it maintains a current ratio of 12.14x, a quick ratio of 11.88x, working capital of $100.39M, a debt-to-equity ratio of -1.53x, a debt ratio of 2.89, free cash flow of $-34.98M (TTM), and net debt of $-102.67M. Figures sourced from SEC EDGAR.
- Market Cap
- $302.65M
- P/E TTM
- -0.96x
- EPS TTM
- $-26.94
- P/B TTM
- -1.38x
- ROE TTM
- 366.30%
- ROA TTM
- -287.85%
- Debt To Equity
- -1.53x
- Free Cash Flow TTM
- $-34.98M
- Net Revenue TTM Growth 1Y
- -8.79%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Surrozen, Inc./DE in?
Surrozen, Inc./DE (SRZN) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does SRZN trade on?
Surrozen, Inc./DE (SRZN) trades on the Nasdaq.
Where is Surrozen, Inc./DE incorporated?
Surrozen, Inc./DE is incorporated in DE.
When was Surrozen, Inc./DE (SRZN)'s most recent SEC filing?
Surrozen, Inc./DE (SRZN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is SRZN's market cap?
Surrozen, Inc./DE (SRZN) has a market capitalization of $302.65M as of 2026-06-30.
What is SRZN's EPS (earnings per share)?
Surrozen, Inc./DE (SRZN)'s trailing twelve month EPS is $-26.94 as of 2026-06-30.
What is SRZN's ROE (return on equity)?
Surrozen, Inc./DE (SRZN)'s trailing twelve month Return on Equity (ROE) is 366.30% as of 2026-06-30.
What is SRZN's ROA (return on assets)?
Surrozen, Inc./DE (SRZN)'s trailing twelve month Return on Assets (ROA) is -287.85% as of 2026-06-30.
What is SRZN's ROIC (return on invested capital)?
Surrozen, Inc./DE (SRZN)'s trailing twelve month Return on Invested Capital (ROIC) is -215.69% as of 2024-03-31.
What is SRZN's EV/EBITDA?
Surrozen, Inc./DE (SRZN)'s trailing twelve month EV/EBITDA is -4.53x as of 2026-06-30.